Nippon Shinyaku Co. Ltd. has divulged azaindole compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, spinal cord injury, Behçet’s disease, atopic dermatitis and idiopathic pulmonary fibrosis, among others.

Pharmaengine Inc. has identified Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Nuvobio Corp. has synthesized peptides reported to be useful for the treatment of Cryptococcus neoformans infection.

Suzhou Ark Biopharmaceutical Co. Ltd. has disclosed phosphodiesterase PDE4 inhibitors.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described immunoproteasome inhibitors reported to be useful for the treatment of systemic lupus erythematosus and arthritis.

Qianhangjiang Pharmaceutical Co. Ltd. has divulged somatostatin peptide analogues acting as somatostatin receptor type 2 (SSTR2) ligands reported to be useful for the treatment of cancer and acromegaly.

Summit Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to a GTPase KRAS (G12D) targeting moiety through a linker acting as KRAS (G12D) inhibitors and degradation inducers reported to be useful for the treatment of cancer.

Shanghai Jemincare Pharmaceutical Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Beijing Primegene Therapeutics Co. Ltd. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, stroke, osteoarthritis, multiple sclerosis, rheumatoid arthritis, atherosclerosis and Alzheimer’s disease, among others.

Pliant Therapeutics Inc. has described integrin αvβ1, integrin αvβ6 and/or integrin αvβ8 antagonists reported to be useful for the treatment of cancer and fibrosis.